Sorry about the formatting. Notice that there is research back 15 years.
1: Zhang W, Shin EJ, Wang T, Lee PH, Pang H, Wie MB, Kim WK, Kim SJ, Huang WH, Wang Y, Zhang W, Hong JS, Kim HC. Related Articles, Links
Abstract 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro.
FASEB J. 2006 Dec;20(14):2496-511.
PMID: 17142799 [PubMed - indexed for MEDLINE]
2: Li G, Cui G, Tzeng NS, Wei SJ, Wang T, Block ML, Hong JS. Related Articles, Links
Free Full Text Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage.
FASEB J. 2005 Apr;19(6):489-96.
PMID: 15790998 [PubMed - indexed for MEDLINE]
3: Zhang W, Qin L, Wang T, Wei SJ, Gao HM, Liu J, Wilson B, Liu B, Zhang W, Kim HC, Hong JS. Related Articles, Links
Free Full Text 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity.
FASEB J. 2005 Mar;19(3):395-7. Epub 2004 Dec 13.
PMID: 15596482 [PubMed - indexed for MEDLINE]
4: Zhang W, Wang T, Qin L, Gao HM, Wilson B, Ali SF, Zhang W, Hong JS, Liu B. Related Articles, Links
Free Full Text Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.
FASEB J. 2004 Mar;18(3):589-91. Epub 2004 Jan 20.
PMID: 14734632 [PubMed - indexed for MEDLINE]
5: Liu Y, Qin L, Li G, Zhang W, An L, Liu B, Hong JS. Related Articles, Links
Free Full Text Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation.
J Pharmacol Exp Ther. 2003 Apr;305(1):212-8.
PMID: 12649371 [PubMed - indexed for MEDLINE]
6: Palmer GC. Related Articles, Links
Abstract Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies.
Curr Drug Targets. 2001 Sep;2(3):241-71. Review.
PMID: 11554551 [PubMed - indexed for MEDLINE]
7: Chase TN, Oh JD, Konitsiotis S. Related Articles, Links
Abstract Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms.
J Neurol. 2000 Apr;247 Suppl 2:II36-42. Review.
PMID: 10991664 [PubMed - indexed for MEDLINE]
8: Verhagen Metman L, Del Dotto P, Blanchet PJ, van den Munckhof P, Chase TN. Related Articles, Links
Abstract Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Amino Acids. 1998;14(1-3):75-82.
PMID: 9871445 [PubMed - indexed for MEDLINE]
9: Verhagen Metman L, Del Dotto P, Natte R, van den Munckhof P, Chase TN. Related Articles, Links
Abstract Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
Neurology. 1998 Jul;51(1):203-6.
PMID: 9674803 [PubMed - indexed for MEDLINE]
10: Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natte R, Chase TN. Related Articles, Links
Abstract A trial of dextromethorphan in parkinsonian patients with motor response complications.
Mov Disord. 1998 May;13(3):414-7.
PMID: 9613730 [PubMed - indexed for MEDLINE]
11: Montastruc JL, Rascol O, Senard JM. Related Articles, Links
Abstract Glutamate antagonists and Parkinson's disease: a review of clinical data.
Neurosci Biobehav Rev. 1997 Jul;21(4):477-80. Review.
PMID: 9195605 [PubMed - indexed for MEDLINE]
12: Kaur S, Starr MS. Related Articles, Links
Abstract Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse.
Eur J Pharmacol. 1995 Jul 4;280(2):159-66.
PMID: 7589181 [PubMed - indexed for MEDLINE]
13: Montastruc JL, Fabre N, Rascol O, Senard JM, Blin O. Related Articles, Links
No abstract N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan.
Mov Disord. 1994 Mar;9(2):242-3. No abstract available.
PMID: 8196695 [PubMed - indexed for MEDLINE]
14: Bonuccelli U, Del Dotto P, Piccini P, Behge F, Corsini GU, Muratorio A. Related Articles, Links
No abstract Dextromethorphan and parkinsonism.
Lancet. 1992 Jul 4;340(8810):53. No abstract available.
PMID: 1351627 [PubMed - indexed for MEDLINE]